Clinical study of temafloxacin

We evaluated the clinical efficacy and safety of temafloxacin (TMFX), a new quinolone antimicrobial agent. TMFX was administrated for 11 respiratory infections and 3 urinary tract infections. The patients received the drug orally for 6 to 14 days at a dose of 150-450mg/day. Clinical effects were goo...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 41; no. Supplement5; pp. 755 - 757
Main Authors Wada, Kouichi, Sega, Hiroyuki, Kawasima, Takasi, Tsukada, Hiroki, Arakawa, Masaaki
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1993
Subjects
temafloxacin
Online AccessGet full text

Cover

More Information
Summary:We evaluated the clinical efficacy and safety of temafloxacin (TMFX), a new quinolone antimicrobial agent. TMFX was administrated for 11 respiratory infections and 3 urinary tract infections. The patients received the drug orally for 6 to 14 days at a dose of 150-450mg/day. Clinical effects were good in all 14 cases. Neither side effects nor abnormal laboratory findings were observed after administration of TMFX.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.41.Supplement5_755